Chimeric Therapeutics Limited (ASX:CHM)

-72.22% (1Y)

Market Cap	11.08M
Revenue (ttm)	2.04M
Net Income (ttm)	-17.83M
Shares Out	2.02B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	992,287
Average Volume	5,052,819
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0030 - 0.0220
Beta	1.51
RSI	57.07
Earnings Date	Aug 29, 2025

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 express...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

In 2024, Chimeric Therapeutics's revenue was 7.46 million, an increase of 65.52% compared to the previous year's 4.51 million. Losses were -12.53 million, -51.65% less than in 2023.